Medicine Matters diabetes

The ultralong-acting, once-daily basal insulin degludec has equivalent cardiovascular safety to that of insulin glargine and reduces hypoglycemia risk in patients with type 2 diabetes, the DEVOTE investigators have reported.

The ADA Presidents Oral Session closed the 2017 American Diabetes Association 77th Scientific Sessions.

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

The HAPO FUS investigators have reported that the increased risk for adiposity in the babies of women with gestational diabetes persists through to later childhood.

The REMOVAL findings show an uncertain effect of metformin on atherosclerosis in overweight patients with type 1 diabetes, and only a transient effect on glycemic outcomes.

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

The latest analyses from the LEADER trial show that liraglutide is effective against recurrent cardiovascular disease and renal events in patients with type 2 diabetes.

Data from the ODYSSEY series of trials, presented at the American Diabetes Association scientific sessions, show that the PCSK9 inhibitor alirocumab reduces atherogenic dyslipidemia in patients with diabetes.

A study of Danish men suggests that the increased risk for diabetes associated with being overweight in childhood may be reversed if people lose their excess weight by young adulthood.

Research shows that a fixed-dose combination of insulin degludec and liraglutide is as effective as a basal–bolus insulin regimen in insulin-dependent patients with type 2 diabetes, and requires just one daily injection.

Symposia on the penultimate day of the 2017 American Diabetes Association 77th Scientific Sessions looked at, among other things, healthy lifestyle matters for patients with diabetes and kidney disease, preserving the beta-cell function, and systemic correlates of diabetic retinopathy.

Day 3 of the 2017 American Diabetes Association 77th Scientific Sessions featured symposia on emerging therapeutic targets and their mechanism of action, exercise and diabetes complications, and pharmacologic strategies in diverse populations.

Symposia on the second day of the 2017 American Diabetes Association 77th Scientific Sessions focused on topics ranging from the mechanistic links between cancer, obesity, and diabetes to novel islet signaling pathways and dealing with the rising costs of insulin.

The opening day of the 2017 American Diabetes Association 77th Scientific Sessions featured symposia on a broad range of topics including the stigma of diabetes, management of diabetic neuropathy, biomarkers of type 1 diabetes, and the role of the intestinal immune system in metabolic disease.

In a lively session on Friday afternoon, presenters looked at the evidence (or lack thereof) underlying dietary guidelines for patients with diabetes.